title: Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.
abstract: Pneumococcal conjugate vaccines (PCV) may reduce nasopharyngeal carriage (NPC) of Streptococcus pneumoniae vaccine strains (VT), but serotype replacement with non-vaccine strains (NVT) has been reported. Bacterial NPC after PHiD-CV vaccination was assessed in the second year of life. Open descriptive study of NPC reported for 414 subjects vaccinated at 3-5 and 12-15 months of age with PHiD-CV with or without prophylactic paracetamol (PP) compared to 336 age-matched PCV-naïve controls. Carriage was assessed prior to and 1, 3, 7 and 12 months after PHiD-CV booster or MenACWY-TT control vaccination at 12-15 months of age. At each visit, carriage of VT was reduced by 22-35% in PHiD-CV recipients. Vaccine efficacy across all visits was 21.7% [95% CI 2.6; 37.0] (26.8% carriage in the PHiD-CV group versus 34.2% in controls). Carriage rates of NVT tended to be higher in PHiD-CV recipients. Pre-booster, these findings were more pronounced when PP had not been administered. No substantial effect of PHiD-CV vaccination was observed on NPC of other bacterial pathogens including non-typeable Haemophilus influenzae. Primary and booster vaccination with PHiD-CV reduced NPC of VT in the second year of life and tended to slightly increase that of NVT in line with previous experience with the 7-valent PCV.
authors.affiliation: Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic. prymula@pmfhk.cz
authors.forename: Roman
authors.initials: R
authors.lastname: Prymula
authors.forename: Irena
authors.initials: I
authors.lastname: Hanovcova
authors.forename: Miroslav
authors.initials: M
authors.lastname: Splino
authors.forename: Pavla
authors.initials: P
authors.lastname: Kriz
authors.forename: Jitka
authors.initials: J
authors.lastname: Motlova
authors.forename: Vera
authors.initials: V
authors.lastname: Lebedova
authors.forename: Patricia
authors.initials: P
authors.lastname: Lommel
authors.forename: Eva
authors.initials: E
authors.lastname: Kaliskova
authors.forename: Thierry
authors.initials: T
authors.lastname: Pascal
authors.forename: Dorota
authors.initials: D
authors.lastname: Borys
authors.forename: Lode
authors.initials: L
authors.lastname: Schuerman
mesh_terms: D002353:Carrier State / Q000517:prevention & control*; D005260:Female; D006192:Haemophilus Infections / Q000517:prevention & control*; D006193:Haemophilus influenzae / Q000302:isolation & purification*; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods; D007223:Infant; D008297:Male; D009305:Nasopharynx / Q000382:microbiology*; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000302:isolation & purification*; D014611:Vaccination / Q000379:methods
chemical_list: C547294:PHiD-CV vaccine; D022242:Pneumococcal Vaccines